Dudediligence.

Lantheus Holdings, Inc

LNTHNASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$378.7MSep ’24$391.1MDec ’24$372.8MMar ’25$378.0MJun ’25$384.0MSep ’25$406.8MDec ’25$377.3MMar ’26$388.2MJun ’26
Net income, by quarter
$131.1MSep ’24−$11.8MDec ’24$72.9MMar ’25$78.8MJun ’25$27.8MSep ’25$54.1MDec ’25$118.4MMar ’26$75.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$425.2M$935.1M$1.30B$1.53B$1.54B
Gross profit$187.7M$581.7M$709.5M$988.3M$942.0M
Operating income−$60.8M$36.2M$364.6M$457.0M$310.8M
Net income−$71.3M$28.1M$326.7M$312.4M$233.6M
Operating cash flow$53.9M$281.8M$305.3M$544.8M$390.1M
Free cash flow$53.9M$21.8M$259.9M$463.8M$390.1M
Cash$98.5M$415.7M$713.7M$912.8M$359.1M
Debt$174.8M$558.1M$562.5M$566.3M$569.4M
Shares outstanding67.7M68.9M69.9M68.5M64.6M